Johnson & Johnson (NYSE: JNJ)

Last Updated: Sep-29-2016 18:46:18

JNJ News & Stock Updates

Click here to read more stories
  • Johnson & Johnson (NYSE: JNJ) Amps Up Drug Pipeline

    5/20/2015: Shares of Johnson & Johnson (NYSE: JNJ) gained roughly 0.5% on news that the firm said it will have 10 or more new drugs enter its pipeline by 2019. The company projects that each drug will produce sales of $1 billion or more.

  • Johnson & Johnson (NYSE: JNJ) Shares Down Pre-Earnings

    4/15/15: Shares of Johnson & Johnson (NYSE: JNJ) slipped nearly 1.5% this afternoon, weighing down the broader Dow Jones Industrial Average. The healthcare giant will announce earnings tomorrow and has struggled over the last year. The company's shares have trailed the S&P 500 by more than 10%.

  • Biotech Boom: (Nasdaq: ABBV), (Nasdaq: PCYC), (NYSE: JNJ)

    Shares of AbbVie Inc. (Nasdaq: ABBV) slipped more than 5% this morning on news that the pharmaceutical giant will purchase Pharmacyclics Inc. (Nasdaq: PCYC) for $21 billion. The deal will give AbbVie access to the very promising blood cancer drug, Imbruvica, although Johnson & Johnson (NYSE: JNJ) currently receives half of the drug's revenue thanks to […]

  • Pandemic Push: (NYSE: JNJ)

    Shares of Johnson & Johnson (NYSE: JNJ) were up marginally in pre-market hours on news that the company has started testing an Ebola-virus vaccine in humans. The company has increased its development of the treatment in response to concerns about Ebola overwhelming hospitals across Western Africa. The company plans to manufacture at least 400,000 doses […]

  • This Big-Cap "Ebola Stock" Is Also a Dividend Aristocrat

    Over the past few weeks, one "clinical stage" pharma firm after another has seen its stock price rise and plummet on rumors about who has the most likely Ebola vaccine.

    I'm not taking you on any wild rides like that. Instead, check out this solid big-cap company that's gearing up for a major Ebola drug trial.

    Now, before the crowd notices, let's take a look - this is not your typical "Ebola stock"...
  • Ebola Solutions: (NYSE: JNJ)

    The Wall Street Journal reports that healthcare holding giant Johnson & Johnson (NYSE: JNJ) announced plans to start testing an Ebola vaccine in humans by January in a partnership with Danish biotech firm Bavarian Nordic (OTCMKTS: BVNRY). Should the testing prove effective and receive regulatory waivers, the firm said it could have up to 250,000 […]

  • The 8 Hot Stocks Starring in Today's M&A Mania

    A burst of mergers and acquisitions dominated today's stock market news.

    M&A activity year-to-date, driven by healthcare, pharmaceuticals, and telecommunications, has already topped $1 trillion. More billion-dollar deals were announced Monday in the healthcare and telecommunications sectors, as well as lucrative transactions in oil and tech.

    And these deals are great news for the investors holding these hot stocks.
  • 12 High-Yield Dividend Aristocrats to Buy for Reliable Income

    Dividend Aristocrats are an exceptional bunch of S&P 500 companies that don't just offer high yield – they have increased shareholders' payouts every year for (at least) the last 25 years.

    Making the list is indeed an accomplishment.

    Industries run the gamut from fast food to financials to oil.

    We’ve narrowed the list to a more manageable dozen names across several sectors...
  • Stock Market Today: It's Easy to Beat Earnings Estimates When You Aim Low

    The stock market today opened higher as earnings continue to be "not as bad as expected" and industrial production shows signs of stabilizing.

    Here's our market roundup for investors:

    • Earnings continue to beat estimates– The third quarter was supposed to be a dismal earnings season but lowered expectations are giving companies a boost. Johnson and Johnson (NYSE: JNJ) and Goldman Sachs Group Inc. (NYSE: GS) reported better-than-expected profits this morning and each offered investors something else to cheer about. JNJ's third-quarter profits fell 7% from last year but its adjusted EPS of $1.25 beat Wall Street's estimates of $1.21. Goldman had a third-quarter profit of $1.51 billion, compared with a year-earlier loss of $393 million and easily beat both earnings and revenue forecasts. Besides the strong earnings, Goldman announced that it would increase its quarterly dividend to 50 cents from 46 cents and JNJ raised its 2012 earnings forecast. JNJ stock is up 1.4% in early trading and GS stock is up 1.0%.

    Decreased expectations have allowed companies to report numbers that might have been disappointing but now look encouraging. JNJ pulled this off as the forecast it issued today for 2012 earnings was lower than the projection it had last quarter. Even though earnings for the most part have beat expectations there is still the uncertainty of the fiscal cliff and slowing economic growth.

    "Investors are cycling back into risk as earnings as well as economic numbers in the U.S. are somewhat better than expected," Chad Morganlander, a Florham Park, NJ-based fund manager at Stifel Nicolaus & Co. told Bloomberg News in a telephone interview. "Economic growth will continue to be sluggish even with the flickers of hope that we've seen this morning."

  • Four Defensive Stocks for a Market Pullback: MCD, MO, CAG, JNJ

    If you looked at just the first-quarter results you could be forgiven for thinking that everything in the stock market is rosy.

    The Dow Jones Industrials and the S&P 500 turned in their best performances since 1998, rising 8.14% and 12.0%, respectively.

    Meanwhile, the Nasdaq was even stronger, riding a tech-stock rally to a gain of nearly 19% – its best yearly start since 1991.

    But as every seasoned investor knows, the markets never go straight up or straight down.

    Prospects for continued strength may seem bright, but the recent five-day slide that took the Dow down almost 550 points might be pointing to something else entirely.

    That's why now is the perfect time to consider shifting at least some of your funds into "defensive" stocks.

    To continue reading, please click here...

Premium Research

Johnson & Johnson (NYSE: JNJ) Profile

Prior Close$119.39
Market Cap$322.57 B
PE Ratio18.77
Johnson & Johnson is engaged in the research and development manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer Pharmaceutical and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care skin care oral care wound care and women's health fields nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective antipsychotic contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management thrombosis vaccines and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction spinal care neurological and sports medicine products; surgical care aesthetics and women's health products. Johnson & Johnson is based in New Brunswick New Jersey.
SymbolCompanyMarket cap
RHHBYRoche Hldg Ltd Spons$214.01 B
PFEPfizer Inc$205.2 B
NVSNovartis Ag$192.59 B
MRKMerck & Company$173.02 B
NVONovo Nordisk A/S$110.82 B
GSKGlaxosmithkline Plc$105.6 B
ABBVAbbvie Inc Common Stock$105.15 B
SNYSanofi-Aventis Sa$98.21 B
BMYBristol-Myers Squibb Company$93.13 B
LLYEli Lilly and Company$89.28 B

JNJ Earnings

1st Quarter Earnings$1.74 (2016-07-19)
2nd Quarter Earnings$1.68 (2016-04-19)
3rd Quarter Earnings$1.44 (2016-01-26)
4th Quarter Earnings$1.49 (2015-10-13)
PE Ratio18.77
EPS Growth7.82%
Recent Earnings$1.74
Annual EPS$6.35
Market Capitalization$322.57 B
Insider Shareholder %0.0011%
Annual Revenue$70.88 B
Number of Shares Outstanding2,750,640 Shares
Institutional Shareholder %65.32%
Annual Net Income$14.86B
TTM Net Profit Margin$20.97
One Year Return31.57%
Three Year Return43.77%
Five Year Return124.11%
Five Year Revenue Growth13.78%
Five Year Earnings Growth30.25%
Five Year Dividend Growth39.81%
Last Quarter EPS$1.74
Annual EPS$6.35
Annual Dividend$3.2
Annual Dividend Yield2.68%
Change in EPS YTD7.82%
PE Ratio18.77
Recent Earnings$1.74
Dividends per Share$0.8
Stock Split Ratio2-1

JNJ Key Stats

Last Price$117.27
Net Change$-2.12 (-1.78%)
Ask Price$117.49
Open Price$118.88
Previous Close Price$119.39
High Price$119.27
Low Price$117.04
Number of Trades29,562
Fifty Two Week High$126.07 (2016-07-20)
Fifty Two Week Low$91.76 (2015-10-01)
Average Daily Volume7,739,114
Share Outstanding2,750,640 Shares
Total Dividend Payout$3.2/yr
Dividend Yield2.68%